Jaume Pons Sells 50,000 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) Stock

ALX Oncology Holdings Inc. (NASDAQ:ALXO) insider Jaume Pons sold 50,000 shares of the company’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $14.20, for a total transaction of $710,000.00. Following the completion of the transaction, the insider now directly owns 604,205 shares in the company, valued at approximately $8,579,711. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jaume Pons also recently made the following trade(s):

• On Thursday, April 4th, Jaume Pons sold 20,000 shares of ALX Oncology stock. The stock was sold at an average price of $11.15, for a total transaction of $223,000.00.

ALX Oncology Stock Down 0.9 %

Shares of NASDAQ:ALXO opened at $15.60 on Friday. The firm’s 50 day moving average price is $13.59 and its 200 day moving average price is $11.97. The stock has a market cap of $780 million, a price-to-earnings ratio of -4.16 and a beta of 1.58. ALX Oncology Holdings Inc. has a fifty-two week low of $3.94 and a fifty-two week high of $17.42. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.05.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.09). As a group, equities research analysts predict that ALX Oncology Holdings Inc. will post -3.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ALXO shares. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research report on Friday, April 12th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of ALX Oncology in a research report on Wednesday, April 10th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $14.00 price target (up previously from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $18.83.

Hedge Funds Weigh In On ALX Oncology

Several hedge funds have recently added to or reduced their stakes in ALXO. Swiss National Bank increased its stake in ALX Oncology by 8.5% in the first quarter. Swiss National Bank now owns 19,200 shares of the company’s stock valued at $324,000 after purchasing an additional 1,500 shares during the last quarter. JPMorgan Chase & Co. increased its stake in ALX Oncology by 21.6% in the first quarter. JPMorgan Chase & Co. now owns 19,237 shares of the company’s stock valued at $326,000 after purchasing an additional 3,417 shares during the last quarter. MetLife Investment Management LLC increased its stake in ALX Oncology by 58.5% in the first quarter. MetLife Investment Management LLC now owns 10,745 shares of the company’s stock valued at $182,000 after purchasing an additional 3,965 shares during the last quarter. BlackRock Inc. increased its stake in ALX Oncology by 1.1% in the first quarter. BlackRock Inc. now owns 1,355,478 shares of the company’s stock valued at $22,907,000 after purchasing an additional 14,907 shares during the last quarter. Finally, Federated Hermes Inc. purchased a new position in ALX Oncology in the first quarter valued at approximately $914,000. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.